DOI QR코드

DOI QR Code

A Study of the Changes of Breast Uptake in Menstrual Cycle on 18F-FDG PET/CT

월경 주기에 따른 18F-FDG PET/CT에서 유방 섭취 변화에 관한 고찰

  • Tak, Yeojin (Dept. of Radiological Technology, Shingu College) ;
  • Park, Min Soo (Dept. of Nuclear Medicine, Severance Hospital, YUHS) ;
  • Lee, Juyoung (Graduate School of Public Health, Yonsei University) ;
  • Park, Hoon-Hee (Dept. of Radiological Technology, Shingu College)
  • 탁여진 (신구대학교 방사선과) ;
  • 박민수 (연세대학교 세브란스병원 핵의학과) ;
  • 이주영 (연세대학교 보건대학원) ;
  • 박훈희 (신구대학교 방사선과)
  • Received : 2015.01.02
  • Accepted : 2015.03.19
  • Published : 2015.03.31

Abstract

$^{18}F-FDG$ PET/CT has been known a useful modality to diagnose high-glucose-using cells such as cancer cells by glucose metabolism of FDG. Mainly, FDG takes on cancer and inflammatory cells; however, there have been FDG uptakes on normal tissues by individual physiological characteristics, occasionally. Especially, in fertile females, unusual FDG uptake of breast changes as the menstrual cycle, and disturb diagnosis. Therefore, the study aimed to evaluate the change of breast FDG uptake in menstrual cycle on $^{18}F-FDG$ PET/CT. 160 females ($34{\pm}3.5$ years old) who do not undergo a gynecologic anamnesis and have regular menstrual cycle over the previous 6 months were examined. They were divided 4 groups (each 40 patients) as flow phase, proliferative phase, ovulatory phase and secretory phase using Pregnancy Calculator 0.14. and history taking. Discovery Ste (GE Healthcare, Milwaukee, Mi, USA) was used a s PET/CT. We analyzed SUVs on accumulated region on breast, and 3 nuclear medicine specialists did the Blind test. SUVs on the Breast were flow phase ($1.64{\pm}0.25$), proliferative phase ($0.93{\pm}0.28$), ovulatory phase ($1.66{\pm}0.26$) and secretory phase ($1.77{\pm}0.28$). It showed high uptake value in secretory, flow phase and ovulatory phase (p<0.05). In gross analysis, the accumulation of breast was divided into 3 grades as comparing with lung and liver. The breast's uptake was equal to lung (Grade I); between lung and liver (Grade II); equal to or greater than liver (Grade III). The results showed high uptake value in secretory, flow phase and ovulatory phase (p<0.05). In fertile females, FDG uptake of breast changed as menstrual cycle, and it available to diagnose breast disease. Therefore, we consider reducing false-negative finding of breast disease, by doing examination on appropriate period through history taking about individual menstrual cycle.

$^{18}F-FDG$ PET/CT는 당대사로 인한 암세포의 비정상적인 섭취를 통해 암을 진단하는 유용한 검사이다. 일반적으로 FDG는 암세포와 염증성 질환에 높은 섭취를 보이나, 환자의 생리적 특성에 따라 정상세포에도 비정상적인 섭취를 나타내기도 한다. 특히 여성 월경 주기에 따른 유방의 비정상적인 섭취는 미세한 유방 병변의 정확한 진단을 저해하는 요인이 될 수 있다. 따라서 본 연구는 월경 주기에 따른 유방의 FDG 섭취 변화를 비교 평가하고자 한다. 평가 대상은 부인과 병력이 없고 6개월 이상 규칙적인 월경 주기를 가진 160명의 여성($34{\pm}3.5$세)을 대상으로 하였다. 환자 문진과 Pregnancy Calculator 0.14.를 이용하여 월경기, 증식기, 배란기, 분비기로 나누어 각각 40명씩 정보를 수집하였으며, PET/CT 장비는 Discovery STe(GE Healthcare, Milwaukee, Mi, USA)를 이용하였다. 분석 방법으로는 월경 주기 별 유방의 SUV 변화를 비교 분석하였으며, 핵의학 전문의 3명을 통해 Blind Test로 육안적 평가를 시행하였다. 유방의 SUV는 월경기($1.64{\pm}0.25$), 증식기($0.93{\pm}0.28$), 배란기($1.66{\pm}0.26$), 분비기($1.77{\pm}0.28$)로 나타났으며 분비기가 가장 높고 월경기와 배란기에서도 높은 섭취를 나타냈다(p<0.05). 또한 육안적 분석에서는 간과 폐의 집적에 대하여 유방의 집적 정도를 단계별로 나누어 폐와 유사한 섭취를 보인 경우(Grade I), 폐와 간 중간 정도의 섭취를 보인 경우(Grade II), 간과 같거나 높은 섭취를 보인 경우(Grade III)로 구분하였으며, 육안적 평가에서도 분비기와 월경기에서 높은 섭취를 보였다(p<0.05). 가임기 여성은 월경 주기에 따라 유방의 18F-FDG 섭취 정도가 변화되며, 특히 미세한 유방 병변을 진단하는데 월경 주기의 정보를 유용하게 활용할 수 있다. 따라서 검사 전 문진을 통하여 가임기 여성의 정확한 월경 주기를 확인하고 적정한 시기를 유도하여 검사를 시행함으로써 유방 질환에 대한 위음성 결과를 감소시킬 수 있을 것으로 사료된다.

Keywords

References

  1. Engel H, Steinert H, Buck A, Berthold T, Rahel A, von Schulthess GK: Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations, J Nucl Med , 37, 441-6, 1996
  2. Strauss LG: Fluorine-18 deoxyglucose and falsepositive results: a major problem in the diagnostics of oncological patients, Eur J Nucl Med, 23, 1409-15, 1996 https://doi.org/10.1007/BF01367602
  3. Cook GJ, Fogelman I, Maisey MN: Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation, Semin Nucl Med, 26, 308-314, 1996 https://doi.org/10.1016/S0001-2998(96)80006-7
  4. Shreve PD, Anzai Y, Wahl R: Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants, Radiographics, 19, 61-77, 1999 https://doi.org/10.1148/radiographics.19.1.g99ja0761
  5. Cook GJ, Wegner EA, Fogelman I: Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine, Eur J Nucl Med Mol Imaging, 26, 1363-1378, 1999 https://doi.org/10.1007/s002590050597
  6. Blodgett TM, Fukui MB, Snyderman CH, et al: Combined PET-CT in the head and neck: part 1-physiologic, altered physiologic, and artifactual FDG uptake, Radiographics, 25, 897-912, 2005 https://doi.org/10.1148/rg.254035156
  7. Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR: Blake MA, Bowel hot spots at PET-CT, Radiographics, 27, 145-159, 2007 https://doi.org/10.1148/rg.271065080
  8. Mijin Yun, Arthur Cho, Jae Hoon Lee, Yun-Jung Choi, Jong Doo Lee, and Chun K. Kim: Physiologic 18F-FDGUptakeintheFallopianTubes at Mid Cycle on PET/CT, J Nucl Med, 51, 682-685, 2010 https://doi.org/10.2967/jnumed.109.074484
  9. Treloar, A. E.; Boyton, R. E.; Behn, B. G.; and Brown, B. W: Variations of the Human Menstrual Cycle through Reproductive Life, International Journal of Fertility, 9, 77-126, 1967
  10. Zangheri B, Messa C, Picchio M, Gianolli L, Landoni C, Fazio F: PET/CT and breast cancer, Eur J Nucl Med Mol Imaging, 31(suppl 1), 135-142, 2004 https://doi.org/10.1007/s00259-004-1536-7
  11. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL: Initial experience with FDG-PET/CT in the evaluation of breast cancer, Eur J Nucl Med Mol Imaging, 33, 254-262, 2006 https://doi.org/10.1007/s00259-005-1835-7
  12. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O: The role of FDG-PET/CT in suspected recurrence of breast cancer, Cancer, 107, 2545-2551, 2006 https://doi.org/10.1002/cncr.22292
  13. Beresford M, Lyburn I , Sanghera B, Makris A, Wong WL: Serial integrated 18F fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma, Breast J, 13, 424-425, 2007 https://doi.org/10.1111/j.1524-4741.2007.00454.x
  14. Rosenberg RD, Hunt WC, Williamson MR, et al: Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico, Radiology, 209, 511, 1998 https://doi.org/10.1148/radiology.209.2.9807581
  15. Kerlikowske K, Grady D, Barclay J, et al: Effect of age, breast density, and family history on the sensitivity of first screening mammography, JAMA, 276, 33-38, 1996 https://doi.org/10.1001/jama.1996.03540010035027
  16. Kavanagh AM, Cawson J , Byrnes G B, et al: Hormone replacement therapy, percent mammographic density, and sensitivity of mammography, Cancer Epidemiol Biomarkers Prev, 14, 1060-1064, 2005 https://doi.org/10.1158/1055-9965.EPI-04-0165